.
BACKGROUND:Two biological subphenotypes in acute respiratory distress syndrome (ARDS) have been identified in retrospective analyses, with differential clinical outcomes and post-hoc responses to investigational treatments. The ability to identify biological subphenotypes in real-time is unknown. We aimed to evaluate the feasibility of using the multisite ISPY COVID Network to prospectively evaluate biological subphenotypes in real-time. METHODS:This prospective, observational, cohort study enrolled patients with ARDS and severe acute hypoxaemic respiratory failure (AHRF) and assessed the feasibility of real-time stratification into biological subphenotypes using plasma concentrations of IL-6, soluble tumour necrosis factor-1 (TNFR1), and clinical variables. Participants were eligible if they were receiving mechanical ventilation, non-invasive positive pressure ventilation, or heated high flow nasal oxygen (at flow rates ≥30 L/min); had severe AHRF (defined by an SpO2 to FiO2 ratio ≤315, calculated with SpO2 ≤97%, or PaO2 to FiO2 ratio <300 if arterial blood gas was available); and the presence of these criteria for less than 48 h. Key exclusion criteria were being younger than 18 years, known pregnancy, being incarcerated, ARDS secondary to trauma, and rapidly improving hypoxaemia. Enrolled patients had to meet inclusion and exclusion criteria at the time of consent and blood draw. Enrolled patients were stratified into either a severe AHRF group (unilateral infiltrate) or an ARDS group (bilateral infiltrates) based on chest imaging at enrolment, determined by the study team. After enrolment, a blood sample (up to 6 mL) was collected and immediately taken to the local laboratory for plasma analysis. Following biomarker quantification participants were allocated to the hypoinflammatory or hyperinflammatory groups. Feasibility was defined a priori as successful real-time biological subphenotyping in greater than 75% of the final 100 enrolled participants. FINDINGS:From June 15, 2023, to Oct 31, 2024, 844 patients at 17 hospitals in the ISPY COVID Network across the USA were screened for the study. After 504 exclusions and two withdrawals of consent, 338 patients were enrolled. 124 (37%) of the enrolled cohort were classified as AHRF, and 214 (63%) were classified as ARDS. 199 (59%) of patients were male and 138 (41%) were female, and the median age at enrolment was 64 years (IQR 54-74). The majority of patients were white (239 [71%]). 250 (74%) of the enrolled cohort completed subphenotype assignment using fresh plasma and were defined as successfully subphenotyped. Successful real-time subphenotyping increased from 59 for the first 100 enrolled participants (59% [95% CI 49-69]) to 82 for the last 100 enrolled participants (82% [73-89]), meeting the predefined feasibility threshold. Median time to subphenotype assignment from blood collection in the overall cohort and the successfully subphenotyped subgroup was 2·2 h (IQR 1·5-19·8) and 1·9 h (1·3-2·3) from the time of blood collection, respectively. The hyperinflammatory subphenotype was identified in 61 (29%) of 214 participants with ARDS and 29 (23%) of the 124 participants with severe AHRF. Clinical outcomes including mortality, organ support-free days and ventilator-free days were worse in patients with hyperinflammatory ARDS compared with those with hypoinflammatory ARDS. INTERPRETATION:Rapid real-time biological subphenotyping for ARDS and severe AHRF in a multisite US hospital network is feasible; and successful real-time subphenotyping both improved over the study time-course and was completed within 2·2 h from study blood collection. These results support the feasibility of real-time precision trials of therapies targeting biological subphenotypes in ARDS. FUNDING:COVID R&D Consortium, Allergan, Amgen, Takeda Pharmaceutical Company, Ingenus Pharmaceuticals, Implicit Bioscience, Johnson & Johnson, Pfizer, Roche-Genentech, Apotex, FAST Grant from Emergent Venture George Mason University, and The Grove Foundation. This work was supported by the US Defense Threat Reduction Agency (MCDC-2013-001). This project has been funded in whole or in part with Federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; and Biomedical Advanced Research and Development Authority (MCDC-2014-001).
Background After an acute coronary syndrome event, secondary prevention is critical but remains suboptimal in underserved populations. Project Rationale Structural barriers, neighborhood deprivation, and clinical inertia create an implementation gap in lipid management, disproportionately affecting vulnerable patients. Project Summary LIICA (Lankenau Initiative to Improve Cardiovascular Access) is a multidisciplinary quality improvement program using the Area Deprivation Index to identify high-risk patients and enroll them in a coordinated pathway led by an advanced practice provider, interventional cardiologist, nurse navigator, community health worker (CHW), and pharmacists. The primary outcome was low-density lipoprotein cholesterol management; secondary outcomes included hemoglobin A1c, Duke Activity Status Index, blood pressure, sleep, anxiety, weight, body mass index, social needs resources, and hospital use. In this pilot cohort at 1 year, achievement of low-density lipoprotein cholesterol <55 mg/dL increased from 6.1% to 58.2%, mean hemoglobin A1c fell from 7.1% to 6.4%, Duke Activity Status Index and anxiety improved, and there were 0% second acute coronary syndrome events. Weight, body mass index, sleep, and blood pressure remained stable. CHWs provided substantial resources. Take-Home Message A multidisciplinary, CHW-led navigation model closes the lipid management implementation gap in high-deprivation populations, converting guideline targets into real-world outcomes.
PURPOSE:Patients with pedal artery occlusive disease have limited options when presenting with chronic limb-threatening ischemia (CLTI). Serration angioplasty (SA) has demonstrated less recoil and improved freedom from reintervention compared with plain old balloon angioplasty within the tibial vessels. We aimed to identify the technical feasibility and clinical outcomes of SA within the pedal (inframalleolar) vasculature in patients with CLTI. MATERIALS AND METHODS:Patient with SA of the pedal vasculature for CLTI from January 01, 2021 to March 31, 2023 were included in this multicenter retrospective study. Pedal vessels were defined as any inframalleolar vessel distal to the talocrural joint. Patient demographics, anatomic and technical details, acute procedural outcomes, and outcomes at the most recent follow-up were collected for analysis. The primary endpoint was technical success, defined as SA with <50% residual target vessel stenosis. Secondary endpoints included freedom from vessel injury, amputation-free survival, clinically-driven target lesion revascularization (CD-TLR), composite major adverse limb events (MALEs), wound healing rate, and improvement in wound, ischemia, and foot infection (WIfI) clinical stage at the most recent follow-up. RESULTS:Of the identified 45 patients managed with pedal SA, median pre-intervention Rutherford classification was 5, and 91.9% of patients had concomitant below-the-knee tibial artery intervention. The most commonly treated artery was the dorsalis pedis (59.2%), with a median diameter SA of 2.5 mm. Residual stenosis was <50% in 93.3% of cases and <30% in 82.2%. Freedom from vessel injury was 93.3% (1 immediate occlusion and 2 bail-out stents). Six-month freedom from major amputation was 93.3%, freedom from pedal CD-TLR was 93.3%, and freedom from MALE was 80.0%. At a median follow-up of 163 days, 48.7% of patients had complete wound healing, with the total frequency of either healed or improving wounds of 79.5%. CONCLUSION:Serration angioplasty of the inframalleolar vasculature in patients with CLTI had high rates of technical success with a low incidence of vessel injury. At a median follow-up of 5.4 months, wound healing was ahead of previously published studies on inframalleolar intervention.Clinical ImpactThis represents the largest series of a specialty balloon used to treat pedal occlusive disease in chronic limb-threatening ischemia patients. As the rate of pedal intervention increases, using new technology to safely achieve luminal gain is crucial for both short- and long-term limb salvage.
Abstract Background Tumor treating fields (TTFields) deliver oscillating electric fields via transducer arrays and is an FDA approved antimitotic therapy for glioblastoma. This study aimed to: (1) utilize whole brain spectroscopic imaging (WBSI)-derived choline/N-acetylaspartate (NAA) maps to define a metabolic target volume (MTV), (2) compare dosimetry profiles between metabolically defined MTVs and conventionally defined anatomically target volumes (ATVs). Methods Ninety glioblastoma patients treated with standard therapy underwent anatomical imaging, and WBSI on 3T-MRI prior to TTFields therapy. The processing steps for WBSI data included field inhomogeneity and eddy current correction, k-space regridding, spatial and Fourier transformation. Quality assurance was assessed using Cramer-Rao lower bounds, line-shape, line-width, CSF contamination, and degree of residual water and lipid signals. Cho/NAA maps, and anatomical images were co-registered and re-sliced. 3D-composite masks were drawn to define ATV covering post-contrast-T1 (PC-T1) and T2-FLAIR abnormalities. A comparable normal-tissue mask was drawn in contralateral normal brain parenchyma by selecting a volume comparable to tumor size and at same slice level. MTV was defined by voxels in tumor region exceeding twice the contralateral mean Cho/NAA value. A comparison was made between MTVs (Cho/NAA abnormalities) and ATVs (PC-T1 and T2-FLAIR). In a pilot sample of 11 patients, finite-element mesh computational modeling (MaxPoint) calculated TTFields power density across 10 regions of interest encompassing both target volumes. Results The Cho/NAA defined MTV (85,422 ± 9,022 voxels) was significantly larger the PC-T1 ATV (36,798 ± 4,301 voxels, p < 0.05), but did not differ significantly from the T2-FLAIR ATV (79,389 ± 9,225 voxels, p = 0.66). While MTV exceeded PC-T1-ATV in all cases, it exceeded T2-FLAIR-ATV in only 69% of cases. MTVs received higher TTFields power-density compared to ATV-T2-FLAIR (3.44 ± 0.69 vs. 2.47 ± 0.25 mW/cm3). Conclusion WBSI derived metabolite maps delineate a more comprehensive representation of tumor’s true spatial extent than conventional MRI and significantly alter dosimetric profiles of TTFields.
AIMS:Heart failure (HF) with preserved (HFpEF) and mildly reduced (HFmrEF) ejection fraction are prevalent, yet frequently underdiagnosed syndromes associated with high morbidity and mortality, impaired quality of life, and escalating healthcare expenditures. Although guideline-directed medications like SGLT2 inhibitors have been shown to reduce the risk of hospitalization and cardiovascular death, their use remains limited and substantial residual risk persists. This trial aims to evaluate the safety and performance of a novel left-atrium-to-coronary-sinus shunt (Edwards APTURE transcatheter shunt system) in HFpEF and HFmrEF patients. METHODS:ALT-FLOW II is a prospective multi-centre, randomized, sham-controlled, double-blinded (patient and assessor) trial. Approximately 100 symptomatic HF patients aged ≥18 years with left ventricular ejection fraction >40% and exercise pulmonary capillary wedge pressure (PCWP) ≥25 mm Hg with a PCWP to right atrial pressure gradient ≥8 mm Hg will be randomized 1:1 to the APTURE shunt vs sham control. Key exclusion criteria include severe HF, significant valvular disease, and more than mild right ventricular dysfunction. The primary endpoints are the safety of the APTURE device at 30 days and change in workload-corrected PCWP normalized to bodyweight at 6 months. Secondary endpoints include changes in patient-reported outcomes, and hemodynamic and echocardiographic parameters through 5 years. The trial will also explore the impact of the device on short-term cardiac remodelling and intra-cardiac flow patterns using multi-modality imaging. CONCLUSIONS:The ALT-FLOW II trial will evaluate the safety and performance of the APTURE system in symptomatic HFpEF and HFmrEF patients with elevated left atrial pressure.